ASCO 2023 | Advances in targeted approaches for AML: magrolimab & pivekimab sunirine
Advances in the management of newly-diagnosed and relapsed acute myeloid leukemia (AML) has been driven in part by the development of novel targeted therapies. In this interview, Catherine Lai, MD, MPH, University of Pennsylvania, Philadelphia, PA, discusses targeted approaches in AML, highlighting the importance of sequencing approaches, as well as new targets such as CD47 with magrolimab and CD123 with pivekimab sunirine, both of which have been evaluated in combination with azacitidine and venetoclax. Dr Lai also highlights patients with TP53 mutations as an area of unmet need as these patients peform worse with the use of cytotoxic chemotherapy as well as azacitidine and venetoclax. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
